Immunodiagnostic Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IDS PLC is a long-established, revenue-generating diagnostics company specializing in immunoassays and automated instruments. It operates globally, providing solutions for both human clinical diagnostics and translational animal research, with a particular noted strength in bone and cartilage metabolism markers. The company is now visibly integrated into the Euroimmun group, suggesting a recent acquisition or strategic merger that expands its reach and resources within the PerkinElmer/Euroimmun diagnostic network.

EndocrinologyAutoimmunityAllergyInfectious DiseasesMusculoskeletal

Technology Platform

Developer and manufacturer of immunoassays (CLIA, ELISA) and random-access automated instrumentation for clinical and research diagnostics.

Opportunities

Leveraging integration with Euroimmun's global sales network for cross-selling and expanded reach.

Growing demand for automated, random-access diagnostic solutions in clinical labs.

Increasing need for reliable biomarkers in preclinical pharmaceutical R&D, especially for musculoskeletal diseases.

Risk Factors

Execution risks associated with post-acquisition integration into the Euroimmun/PerkinElmer structure.

Intense competition from large, diversified IVD corporations in core assay markets.

Dependence on regulatory approvals and favorable reimbursement policies for diagnostic tests.

Competitive Landscape

IDS competes in the broad immunoassay market against global giants like Roche, Abbott, Siemens Healthineers, and Beckman Coulter (Danaher). Its niche in bone/cartilage markers and animal research assays provides some differentiation, but it faces competition from specialized players like QuidelOrtho and numerous research reagent companies in those segments.

More companies in Diagnostics & Precision Medicine →More companies in Belgium →